|
|||||
|
|
EGFR Mutation Testing Practice in Advanced Non-Small Cell Lung Cancer |
|
| Authors: | Jair Bar Arnold Cyjon Dov Flex Hadas Sorotsky Haim Biran Julia Dudnik Nili Peylan-Ramu Nir Peled Hovav Nechushtan Maya Gips Rivka Katsnelson Shoshana Keren Rosenberg Ofer Merimsky Amir Onn Maya Gottfried |
| Affiliation: | 1. Department of Oncology, Institute of Oncology, Sheba Medical Center, Tel Hashomer, 52621, Ramat Gan, Israel 11. Sackler Faculty of Medicine, Tel Aviv University, Ramat Aviv, Israel 2. Department of Oncology, Assaf Harofeh Medical Center, Zerifin, Israel 3. Department of Oncology, Rabin Medical Center, Beilinson, Petach Tikva, Israel 4. Department of Oncology, Hadassah Medical Center and Hebrew University-Hadassah Medical School, Jerusalem, Israel 5. Department of Oncology, Soroka Medical Center, Ben-Gurion University of the Negev, Beersheba, Israel 6. Department of Oncology, Shaare Zedek Medical Center, Hebrew University-Hadassah Medical School, Jerusalem, Israel 7. Department of Oncology, Kaplan Medical Center, Rehovot, Hebrew University Medical School, Jerusalem, Israel 8. Department of Oncology, Lin Medical Center, Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel 9. Department of Oncology, Sourasky Tel Aviv Medical Center, Tel Aviv, Israel 10. Department of Oncology, Meir Medical Center, Kfar Saba, Israel |
| Abstract: | PurposeTesting tumor samples for the presence of a mutation in the epithelial growth factor receptor (EGFR) gene is recommended for advanced non-squamous non-small cell lung cancer (NSCLC) patients. We aimed to collect data about common practice among Medical Oncologists treating lung cancer patients, regarding EGFR mutation testing in advanced NSCLC patients.MethodsAn internet-based survey was conducted among members of the Israeli Society for Clinical Oncology and Radiotherapy involved in the treatment of lung cancer patients.Results24 Oncologists participated in the survey. The participants encompass the Oncologists treating most of the lung cancer patients in Israel. 79 % of them use EGFR testing routinely for all advanced NSCLC patients. Opinions were split regarding the preferable biopsy site for EGFR testing material. 60 % of participants recommend waiting for EGFR test results prior to initiation of first-line therapy.ConclusionsEGFR testing is requested in Israel routinely by most treating Oncologists for all advanced NSCLC patients, regardless of histology. In most cases, systemic treatment is deferred until the results of this test are received. |
| Keywords: | |
| 本文献已被 SpringerLink 等数据库收录！ | |